Abbreviated Name

Colon Ref Set App: Disis (2008)

Lead Investigator

Disis, Mary L — University of Washington

Coordinating Investigator

Disis, Mary L — University of Washington

Involved Investigators

• Feng, Ziding — Fred Hutchinson Cancer Center
• Disis, Mary L — University of Washington

Abstact

Aims

To validate the diagnostic value of a panel of serum antibodies (cathepsin D, p53, cyclin B1, topoisomerase IIalpha, IGFBP2, CEA) for the early detection of colorectal cancer.

Analytic Method

We will run ELISA blinded to case status, data along with our prediction of disease status for each sample, will be sent to EDRN-DMCC at Fred Hutchinson Cancer Research Center for statistical analysis. DMCC already has the combination role from our preliminary study. Our preliminary data suggested that at high specificity 90%, sensitivity is 57%. With n=50 in each group, we have more than 80% power to confirm this level of sensitivity against an inferior sensitivity of 37% at 90% specificity comparing CRC versus normal controls. We understand that the reference set is not powered for definitive validation but to help prioritization. We did not have the data on patients with adenoma but the performance on early-stage CRC suggests that it is possible our marker panel could detection early lesions like adenoma,

Comments

Goodell V, Lu H, Delong J, Disis ML. Antibody Immunity to a Panel of Oncogenic Proteins May Predict Presence of Colorectal Cancer and Stage of Disease. Manuscript in preparation.

Biomarkers

• CCNB1
• CEACAM5
• CTAG1B
• CTSD
• ERBB2
• IGFBP2
• TOP2A
• TP53

Data Collections

• No data available at this time for this protocol

 Team Project

Protocol ID

249

Field of Research

Proteomics

Collaborative Group

G.I. and Other Associated Cancers Research Group

Cancer Types

• Malignant neoplasm of colon